In a nutshell This study aimed to investigate if ibrutinib was safe and effective as a salvage treatment after stem cell transplant in patients with chronic lymphocytic leukemia. This study concluded that ibrutinib is safe and effective as a salvage treatment in these patients. Some background Allogeneic...
Read MoreCurrent treatment status-Undergoing active treatment-Progressive despite treatment Posts on Medivizor
Evaluating stem cell transplant outcomes for patients classical Hodgkin’s lymphoma
In a nutshell This study looked at the outcomes of autologous stem cell transplantation (ASCT) to treat recurrent classical Hodgkin’s lymphoma (cHL). This study concluded that ASCT is effective, with patients who responded after the transplant having the best outcomes. Some background cHL is usually treated with chemotherapy and...
Read MoreEvaluating BEGEV chemotherapy before a stem cell transplant for hard-to-treat Hodgkin lymphoma
In a nutshell This study evaluated the effectiveness of BEGEV chemotherapy for patients with relapsed or unresponsive Hodgkin lymphoma (HL) before a stem cell transplant. The authors concluded that this regimen was safe and effective for these patients. Some background Chemotherapy, followed by a stem cell transplant (SCT), remains the standard of...
Read MoreEvaluating long-term treatment with copanlisib for B-cell lymphoma
In a nutshell This looked at the safety and effectiveness of copanlisib (Aliqopa) for B-cell lymphoma that returned after previous treatment. This study found that long-term copanlisib treatment was safe and effective. Some background Indolent (painless) B-cell lymphoma is a slow-growing blood cancer. B-cell lymphoma that comes back or...
Read MoreAsciminib as a treatment option for patients with chronic myeloid leukemia after kinase inhibitor failure
In a nutshell This study aimed to investigate if asciminib was effective in patients with chronic myeloid leukemia who had resistance or unacceptable side effects to other tyrosine kinase inhibitors. This study concluded that asciminib showed promise in these patients. Some background Asciminib is a...
Read MoreManaging advanced phase chronic myeloid leukemia
In a nutshell This study reviewed treatment options for advanced phase chronic myeloid leukemia. This study concluded that managing advanced phase chronic myeloid leukemia remains challenging and treatment options include tyrosine kinase inhibitors, chemotherapy, and transplant. Some background Chronic myeloid leukemia (CML) can be...
Read MoreSearching for patients with relapsed or unresponsive chronic lymphocytic leukemia to test an immune cell-stimulating treatment
In a nutshell This study is looking for patients with relapsed or unresponsive chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) to test IOV-2001, a treatment that boosts cancer-killing immune cells. The main outcome that will be measured is how well patients respond to treatment. This study is recruiting in Columbus, OH,...
Read MoreEvaluating pembrolizumab for patients with primary mediastinal large B-cell lymphoma that has come back or stopped responding to treatment
In a nutshell This study evaluated the safety and effectiveness of pembrolizumab (Keytruda) for patients with primary mediastinal large B-cell lymphoma (PMBCL) that has come back or stopped responding to treatment. This study concluded that pembrolizumab was safe and effective for these patients. Some background PMBCL is one rare and aggressive type...
Read MoreHow effective and safe is acalabrutinib compared to other treatments for patients with mantle cell lymphoma?
In a nutshell This study compared the effectiveness and safety of acalabrutinib (Calquence) to other targeted therapies for patients with mantle cell lymphoma (MCL). The authors found that acalabrutinib was just as safe and more effective for these patients. Some background MCL is a type of non-Hodgkin's lymphoma treated in...
Read MoreCan durvalumab improve the effectiveness of treatment for patients with SCLC?
In a nutshell This study examined the effectiveness and safety of adding durvalumab (Imfinzi) to platinum-etoposide to treat patients with small-cell lung carcinoma (SCLC). The authors found that durvalumab was well-tolerated and improved survival outcomes. Some background Small cell lung carcinoma (SCLC) is a type of lung cancer that...
Read MoreEncorafenib, cetuximab and binimetinib combined treatment improves survival of patients with advanced colorectal cancer
In a nutshell This study investigated whether treatment with encorafenib (Braftovi), binimetinib (Mektovi), and cetuximab (Erbitux) combined would increase survival in advanced colorectal cancer (CRC). Researchers suggested that this combined therapy increases the survival of patients with metastatic (spread to other parts of the...
Read MoreEvaluating a triplet regimen for patients with relapsed or refractory MM after lenalidomide therapy
In a nutshell This study examined if PBD (pomalidomide, bortezomib, dexamethasone) was safe and effective in patients with multiple myeloma after lenalidomide (Revlimid) treatment. The authors concluded that pomalidomide improved survival without tumor growth or spread but increased side effects. Some background...
Read More
